Related Experiment Videos
In vitro activity of cefsulodin against multi-resistant isolates of Pseudomonas aeruginosa
S M Qadri1, O Billington, B A Cunha
1King Faisal Specialist Hospital, Riyadh, Saudi Arabia.
Abstract:
Clinical isolates of Pseudomonas aeruginosa from 245 patients with different infections were tested to determine their in vitro susceptibility to cefsulodin and other anti-pseudomonad antibiotics. Cefsulodin inhibited 90% of the isolates as compared with 89% by ceftazidime, 84% by piperacillin and 73% by ticarcillin. Of the three aminoglycosides used, gentamycin (60%) and netilmycin (77%) were less inhibitory. Amikacin was the most active, inhibiting 92% of the clinical isolates. Over 60% of the isolates resistant to ticarcillin and piperacillin were susceptible to cephalosporin and aminoglycosides used. Among cefsulodin-resistant isolates, ceftazidime was active against 67% and amikacin and netilmycin against 71% of isolates. Sixty percent of ceftazidime-resistant strains were susceptible to cefsulodin.
Insights
Cefsulodin and amikacin show high in vitro activity against Pseudomonas aeruginosa clinical isolates. Amikacin demonstrated the highest inhibition rate, suggesting its potential in treating Pseudomonas aeruginosa infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Pseudomonas aeruginosa is a significant opportunistic pathogen causing various infections.
- Antibiotic resistance in P. aeruginosa necessitates ongoing surveillance of antimicrobial susceptibility.
- Evaluating novel and existing anti-pseudomonad agents is crucial for effective treatment strategies.
Purpose of the Study:
- To assess the in vitro susceptibility of clinical Pseudomonas aeruginosa isolates to cefsulodin.
- To compare the efficacy of cefsulodin with other anti-pseudomonad antibiotics, including cephalosporins and aminoglycosides.
- To identify the most effective antibiotic agents against a diverse collection of clinical P. aeruginosa isolates.
Main Methods:
- Collected clinical isolates of Pseudomonas aeruginosa from 245 patients with diverse infections.
- Performed in vitro susceptibility testing using cefsulodin and a panel of other anti-pseudomonad antibiotics.
- Determined inhibition percentages for each antibiotic against the tested isolates.
Main Results:
- Cefsulodin inhibited 90% of isolates, comparable to ceftazidime (89%) and amikacin (92%).
- Amikacin exhibited the highest overall activity (92%), followed by cefsulodin (90%) and ceftazidime (89%).
- A significant proportion of isolates resistant to ticarcillin and piperacillin remained susceptible to cefsulodin, ceftazidime, and amikacin.
Conclusions:
- Cefsulodin demonstrates potent in vitro activity against a majority of clinical Pseudomonas aeruginosa isolates.
- Amikacin is the most active aminoglycoside tested, showing broad-spectrum efficacy.
- These findings highlight the importance of antibiotic susceptibility testing for guiding treatment decisions in P. aeruginosa infections.